How biomarker research can pave a way for early treatment

Over the past three decades, significant progress has been made in the development of diagnostic methods for prion diseases. Biochemical markers and MRI in prion diseases were among the first clinical diagnostic criteria used in the diagnosis of a neurodegenerative disease. Advances in seeded amplification assays, such as PrPSc real-time quaking-induced conversion and protein misfolding cyclic amplification, have improved the accuracy of diagnosis, and blood-based biomarkers are now also being discussed. Research into biomarkers remains crucial. It is currently focused on the detection of abnormalities at early stages and the development of non-invasive methods for sampling. The aim of this presentation is to present the current state of biomarker research, with a focus on non-invasive methods and preclinical stages, as biomarkers will become increasingly important in the clinical evaluation of new therapeutics.